0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DLL4

DLL4

Brief Information

Name:Delta-like protein 4
Target Synonym:Delta-Like 4 Homolog,Delta-Like Protein 4,DLL4,Delta4,Notch Ligand Delta-2,Delta Like Canonical Notch Ligand 4,Notch Ligand DLL4,Delta-Like 4 Homolog (Drosophila),AOS6,Hdelta2,Delta 4,Delta-Like 4 (Drosophila),Delta Ligand 4,Drosophila Delta Homolog 4,Del
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
DL4-H5227 Human Human DLL4 Protein, His Tag
DL4-H5227-structure
DL4-H5227-sds
DL4-H5227-elisa_1
DL4-H5259 Human Human DLL4 Protein, Fc Tag
DL4-H5259-structure
DL4-H5259-sds
DL4-H5259-elisa_1

Part of Bioactivity data

DL4-H5227-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human NOTCH2, Fc Tag (Cat. No. NO2-H5255) on Protein A Biosensor, can bind Human DLL4, His Tag (Cat. No. DL4-H5227) with an affinity constant of 77.6 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

DL4-H5227-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human NOTCH1, Fc Tag (Cat. No. NO1-H5255) on Protein A Biosensor, can bind Human DLL4, His Tag (Cat. No. DL4-H5227) with an affinity constant of 67.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

DLL4,Delta4

Background

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Navicixizumab OMP-305B83 Phase 1 Clinical Oncomed Pharmaceuticals Ovarian Neoplasms; Solid tumours; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase 2 Clinical Abbvie Inc Solid tumours; Neoplasms; Colorectal Neoplasms Details
TR-009 ABL001-ABL Bio; ABL-001-ABL Bio; NOV-1501; ES-104; CTX-009 Phase 2 Clinical Abl Bio Solid tumours; Neoplasms; Bile Duct Neoplasms Details

This web search service is supported by Google Inc.

totop